Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 4, 2022 Khosla Ventures Acquisition Co. (the "Company") received a letter (the "Nasdaq Letter") from the Listing Qualifications staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that, as a result of the resignation of Jagdeep Singh, as previously disclosed, from the Company's board of directors and its audit committee, the Company is not in compliance with Nasdaq Listing Rule 5605, which requires that the Company's Audit Committee be comprised of at least three directors, all of whom are independent pursuant to the rules of Nasdaq and applicable law.

The Nasdaq Letter further provided that, pursuant to Nasdaq Listing Rule 5605(c)(4), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605, which cure period will expire on the earlier of the date of the Company's next annual shareholders' meeting or February 10, 2023, or, if the next annual shareholders' meeting is held before August 9, 2022, then the cure period will expire on August 9, 2022.

The Company must submit documentation, including the biography of any new director, evidencing compliance with the Nasdaq Listing Rule 5605 no later than the compliance date described above. The Company is working diligently to comply with Nasdaq's audit committee requirements as set forth in the Nasdaq Listing Rule 5605 within the cure period provided by Nasdaq, and expects to evidence compliance to Nasdaq no later than the compliance date.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses